Alterity Therapeutics Files 6-K, Incorporates Director's Interest Notice
Ticker: PRNAF · Form: 6-K · Filed: Nov 24, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Nov 24, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing-update, director-interests
TL;DR
Alterity Therapeutics files 6-K, includes director's interest notice, incorporates into S-8/F-3 filings.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on November 24, 2025, to incorporate by reference into several of its Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which is a Final Director's Interest notice. The company, formerly known as Prana Biotechnology Ltd, is a development stage enterprise based in Melbourne, Australia.
Why It Matters
This filing is procedural, incorporating existing information into broader registration statements, which is relevant for investors tracking the company's ongoing compliance and disclosures.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previously disclosed information, posing no new immediate risks.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- Prana Biotechnology Ltd (company) — Former company name
- November 24, 2025 (date) — Filing date
- Form S-8 (document) — Incorporated by reference into
- Form F-3 (document) — Incorporated by reference into
- Exhibit 99.1 (document) — Included in filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to incorporate by reference Exhibit 99.1, a Final Director's Interest notice, into the company's existing Registration Statements on Form S-8 and Form F-3.
When was this Form 6-K filed?
This Form 6-K was filed on November 24, 2025.
What is Alterity Therapeutics Limited's former company name?
Alterity Therapeutics Limited's former company name was Prana Biotechnology Ltd.
What type of company is Alterity Therapeutics Limited?
Alterity Therapeutics Limited is described as a development stage enterprise.
Which specific exhibits are submitted with this Form 6-K?
The filing indicates that Exhibit 99.1, a Final Director's Interest notice, is submitted.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 14.1 · Accepted 2025-11-24 07:22:46
Filing Documents
- ea0266894-6k_alterity.htm (6-K) — 14KB
- ea026689401ex99-1_alterity.htm (EX-99.1) — 17KB
- 0001213900-25-113843.txt ( ) — 32KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 24, 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Final Director’s Interest Notice - Kempler 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Julian Babarczy Julian Babarczy Chairman Date: November 24, 2025 2